Edition:
United States

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.96USD
26 May 2017
Change (% chg)

$-0.04 (-2.00%)
Prev Close
$2.00
Open
$1.98
Day's High
$1.98
Day's Low
$1.86
Volume
8,851
Avg. Vol
23,862
52-wk High
$7.96
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Onconova Therapeutics Q1 loss per share $1.23
Monday, 15 May 2017 08:30am EDT 

May 15 (Reuters) - Onconova Therapeutics Inc :Onconova therapeutics, inc. Reports recent business highlights and first quarter 2017 financial results.Q1 revenue $200,000 versus $1.5 million.Onconova therapeutics inc - believes that its current cash and cash equivalents will be sufficient to fund its ongoing trials and operations to end of 2017.Onconova therapeutics inc - cash and cash equivalents as of march 31, 2017, totaled $15.4 million, compared to $21.4 million as of december 31, 2016.Q1 loss per share $1.23.Q1 earnings per share view $-1.01, revenue view $160000.00 -- Thomson Reuters I/B/E/S.  Full Article

Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics
Monday, 1 May 2017 12:28pm EDT 

May 1 (Reuters) - Onconova Therapeutics Inc :Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics Inc as of April 21 - sec filing.  Full Article

ONCONOVA THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK AT $2.10/SHARE
Friday, 21 Apr 2017 09:41am EDT 

April 21 (Reuters) - Onconova Therapeutics Inc :ONCONOVA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.48 MILLION COMMON SHARES PRICED AT $2.10PER SHARE.  Full Article

Onconova Therapeutics reports proposed public offering of common stock
Thursday, 20 Apr 2017 07:47pm EDT 

April 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics announces proposed public offering of common stock.Onconova Therapeutics Inc - intends to use net proceeds from offering to support development of rigosertib for treatment in higher risk mds.  Full Article

Onconova Therapeutics says entered market issuance sales agreement with FBR Capital
Thursday, 20 Apr 2017 05:55pm EDT 

April 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics- on dec. 5, 2016, co entered into at market issuance sales agreement with FBR capital to create an at--market equity program.Onconova Therapeutics Inc - effective april 19, 2017, company terminated sales agreement and related atm program - sec filing.Onconova Therapeutics Inc - has decided to terminate sales agreement because it does not intend to utilize sales agreement to raise additional capital.Onconova Therapeutics Inc - company will not incur any termination penalties as a result of its termination of sales agreement.  Full Article

Onconova Therapeutics reports recent business highlights
Monday, 27 Mar 2017 07:00am EDT 

Onconova Therapeutics Inc : Onconova Therapeutics, Inc. reports recent business highlights and year-end 2016 financial results . Onconova Therapeutics Inc - co believes its current cash, cash equivalents will be sufficient to fund ongoing trials and operations into Q4 of 2017 . Onconova Therapeutics Inc - cash and cash equivalents as of December 31, 2016, totaled $21.4 million, compared to $19.8 million as of December 31, 2015 .Onconova Therapeutics Inc - enrollment on track for inspire pivotal trial of IV Rigosertib in 2nd line HR-MDS.  Full Article

Onconova presents phase 2 data from oral Rigosertib and Azacitidine combination trial
Monday, 5 Dec 2016 07:01am EST 

Onconova Therapeutics Inc : Onconova presents phase 2 data from oral Rigosertib and Azacitidine combination trial in higher-risk myelodysplastic syndromes (HR-MDS) at 2016 ASH annual meeting .Onconova Therapeutics Inc says 35% complete remission (CR) rate for combination in 1(st)-line higher-risk MDS patients seen.  Full Article

Onconova Therapeutics reports Q3 loss per share of $0.29
Monday, 14 Nov 2016 07:01am EST 

Onconova Therapeutics Inc : Onconova Therapeutics qtrly loss per share $0.29 . Onconova therapeutics reports recent business highlights and third quarter 2016 financial results .Q3 revenue $1.7 million versus $1.6 million.  Full Article

Onconova Therapeutics announces plan of termination to reduce a number of positions
Tuesday, 30 Aug 2016 05:12pm EDT 

Onconova Therapeutics : On August 30, communicated to certain employees its plan of termination to reduce a number of positions effective as of August 30 . Estimates net reduction to be about 6 employees, which represents about 21 percent of its workforce - SEC filing .As a result of workforce reduction, estimates will have annual net savings of about $1.4 million.  Full Article

Premkumar Reddy reports a stake of 5.8 pct in Onconova Therapeutics
Friday, 19 Aug 2016 03:45pm EDT 

:Premkumar Reddy reports a stake of 5.8 pct in Onconova Therapeutics Inc as of July 29, 2016 - SEC Filing.  Full Article

More From Around the Web

BRIEF-Onconova Therapeutics Q1 loss per share $1.23

* Onconova therapeutics, inc. Reports recent business highlights and first quarter 2017 financial results